We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

2gt9

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2gt9.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2gt9.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2gt9| PDB=2gt9 | SCENE= }}
{{STRUCTURE_2gt9| PDB=2gt9 | SCENE= }}
-
'''Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide'''
+
===Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide===
-
==Overview==
+
<!--
-
Small structural changes in peptides presented by major histocompatibility complex (MHC) molecules often result in large changes in immunogenicity, supporting the notion that T cell receptors are exquisitely sensitive to antigen structure. Yet there are striking examples of TCR recognition of structurally dissimilar ligands. The resulting unpredictability of how T cells will respond to different or modified antigens impacts both our understanding of the physical bases for TCR specificity as well as efforts to engineer peptides for immunomodulation. In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. Two overlapping epitopes spanning amino acid residues 26 through 35 are of particular interest: numerous clinical studies have been performed using variants of the MART-1 26-35 decamer, although only the 27-35 nonamer has been found on the surface of targeted melanoma cells. Here, we show that the 26-35 and 27-35 peptides adopt strikingly different conformations when bound to HLA-A2. Nevertheless, clonally distinct MART-1(26/27-35)-reactive T cells show broad cross-reactivity towards these ligands. Simultaneously, however, many of the cross-reactive T cells remain unable to recognize anchor-modified variants with very subtle structural differences. These dichotomous observations challenge our thinking about how structural information on unligated peptide/MHC complexes should be best used when addressing questions of TCR specificity. Our findings also indicate that caution is warranted in the design of immunotherapeutics based on the MART-1 26/27-35 epitopes, as neither cross-reactivity nor selectivity is predictable based on the analysis of the structures alone.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17719062}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17719062 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17719062}}
==Disease==
==Disease==
Line 34: Line 38:
[[Category: Mhc classi]]
[[Category: Mhc classi]]
[[Category: X-ray crystallography]]
[[Category: X-ray crystallography]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:30:21 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 03:34:18 2008''

Revision as of 00:34, 29 July 2008

Image:2gt9.png

Template:STRUCTURE 2gt9

Contents

Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide

Template:ABSTRACT PUBMED 17719062

Disease

Known disease associated with this structure: Hypoproteinemia, hypercatabolic OMIM:[109700]

About this Structure

2GT9 is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition., Borbulevych OY, Insaidoo FK, Baxter TK, Powell DJ Jr, Johnson LA, Restifo NP, Baker BM, J Mol Biol. 2007 Oct 5;372(5):1123-36. Epub 2007 Jul 26. PMID:17719062

Page seeded by OCA on Tue Jul 29 03:34:18 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2gt9"
Personal tools